Fig. 1 · Structure

Documents & Downloads

Eravacycline (TP-434)

Cat. No. A13887 CAS 1207283-85-9
TP-434 is a novel, broad-spectrum fluorocycline antibiotic with activity against bacteria expressing major antibiotic resistance mechanisms including tetracycline-specific efflux and ribosomal-protection.

In Stock

Publications for Eravacycline

4 publications citing this product

  1. Hitender Gautam, .et al. , Indian J Med Microbiol, 2024, Mar-Apr:48:100565 PMID: 38522746
  2. Zewen Wen, .et al. , J Antibiot (Tokyo), 2022, Sep;75(9):498-508 PMID: 35896611
  3. Fan Zhang, .et al. , BMC Microbiol, 2018, 18: 211 PMID: 30545293
  4. Jin-xin Zheng, .et al. , Emerg Microbes Infect, 2018, 7: 139 PMID: 30068997

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

TP-434 (eravacycline) inhibits bacterial protein synthesis and competes for tetracycline binding to purified 70S ribosomes. In cell-free assays, the translation IC50 was 0.29 ± 0.09 μg/ml (mean ± SD), and the ribosome-binding competition IC50 was 0.22 ± 0.07 μM. The binding result supports overlapping binding sites; it is not a dissociation constant. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Tetracycline  

In Vitro Studies

Eravacycline activity varied across clinical-isolate species panels. E. coli isolates had MIC50/MIC90 values of 0.25/0.5 μg/ml (n = 445), whereas P. aeruginosa (n = 145) and B. cenocepacia (n = 10) each had values of 8/32 μg/ml. These distributions establish a species-dependent in vitro profile and do not establish clinical efficacy. [3]

Cell-free inhibition of bacterial translation

Biochemical assay · E. coli-coupled in vitro transcription/translation with firefly luciferase readout; no added Tet(M). [1,2]

TP-434 inhibited the cell-free reporter relative to untreated reactions. Tetracycline served as a tetracycline-class comparator and linezolid as a non-tetracycline translation-inhibitor comparator. Reported values are mean IC50 ± SD; methods specify at least two independent experiments.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of luminescence relative to untreated reactions, without Tet(M)IC50 0.29 ± 0.09 μg/ml (mean ± SD)[1,2]
Tetracycline comparator, without Tet(M)IC50 1.26 ± 0.48 μg/ml (mean ± SD)[1,2]
Linezolid comparator, without Tet(M)IC50 1.30 ± 0.28 μg/ml (mean ± SD)[1,2]

Literature-Reported Treatment Conditions

Treatment concentration
TP-434: 0.01–10 μg/ml titration
Exposure duration
1 h at 37°C
Method
Cell-free coupled transcription/translation assay
Co-treatment
No combination treatment; selected result has no added Tet(M).
Reported limits
Compound solvent is not specified in the selected antibiotic/assay methods. Exact number of independent experiments beyond at least two is not supplied.
Methods and source locations

Compound reported in the paper: TP-434 (eravacycline); Compound label in the paper: TP-434

Compound-level research findings. The tested material was not an Adooq lot; salt equivalence and lot-specific performance are not established.

sec3-sec4; sec9; Table 1; Figure 2; Erratum paragraph and corrected Table 1

Inhibition of luminescence relative to untreated reactions, without Tet(M): Coupled transcription/translation, luciferase luminescence — sec9; Table 1 TP-434 row, column identified as Without Tet(M) by 2015 erratum; Figure 2; Corrected Table 1, Without Tet(M) column; corresponding antibiotic row

Tetracycline comparator, without Tet(M): Same coupled transcription/translation assay — sec9; Table 1 tetracycline row, corrected Without Tet(M) column; Corrected Table 1, Without Tet(M) column; corresponding antibiotic row

Linezolid comparator, without Tet(M): Same coupled transcription/translation assay — Table 1 linezolid row, corrected Without Tet(M) column; Corrected Table 1, Without Tet(M) column; corresponding antibiotic row

Competition for tetracycline binding to purified ribosomes

Biochemical assay · Purified E. coli 70S ribosomes; competition with radiolabeled tetracycline. [1]

TP-434 displaced radiolabeled tetracycline, supporting at least partially overlapping ribosome-binding sites. Tigecycline gave a similar reported competition IC50. Erythromycin failed to compete up to 100 μM. This is a competition assay, not a dissociation-constant measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Competition for [3H]tetracycline bindingIC50 0.22 ± 0.07 μM[1]
Tigecycline comparator in radioligand competitionIC50 0.22 ± 0.08 μM[1]
Unlabeled tetracycline comparator in radioligand competitionIC50 3.00 ± 1.15 μM[1]
Erythromycin negative competition controlCompetition result No competition observed up to 100 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
TP-434: 0.01–10 μM titration
Exposure duration
2 h at room temperature
Method
Purified-ribosome radioligand competition; retained radiolabel quantified by scintillation
Co-treatment
Fixed radiolabeled tetracycline is an assay tracer, not combination efficacy.
Reported limits
The ± dispersion type is not defined explicitly for the binding values in the selected methods/results/caption; do not relabel it SD or SEM. Exact n beyond at least two independent experiments is not specified. Compound solvent not specified.
Methods and source locations

Compound reported in the paper: TP-434 (eravacycline); Compound label in the paper: TP-434

Compound-level research findings. The tested material was not an Adooq lot; salt equivalence and lot-specific performance are not established.

sec3; sec5; sec10 first paragraph; Figures 1 and 3

Competition for [3H]tetracycline binding: Competition assay with 0.4 μM E. coli 70S ribosomes and 8 μM [3H]tetracycline; at least two independent experiments — sec5; sec10 first paragraph; Figure 3 and caption

Tigecycline comparator in radioligand competition: Same purified-ribosome competition assay — sec10 first paragraph; Figure 3

Unlabeled tetracycline comparator in radioligand competition: Same purified-ribosome competition assay — sec10 first paragraph; Figure 3

Erythromycin negative competition control: Same purified-ribosome competition assay — sec10 first paragraph; Figure 3

Species-dependent susceptibility in a clinical-isolate panel

Cell-based study · Clinical Gram-negative aerobic isolates; selected Table 1 species panels: E. coli (445), P. aeruginosa (145), B. cenocepacia (10). [3]

One susceptibility-panel design is represented by a common high-sample species and the two explicitly weaker species panels. MIC50/MIC90 values describe isolate distributions, not cellular IC50 values or patient response. Species-appropriate CLSI quality-control strains and comparator antibiotics were included.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Growth inhibition across 445 E. coli clinical isolatesMIC50 / MIC90 0.25 / 0.5 μg/ml; range ≤0.016–4 μg/ml[3]
Growth inhibition across 145 P. aeruginosa clinical isolatesMIC50 / MIC90 8 / 32 μg/ml; range 1–>32 μg/ml[3]
Growth inhibition across 10 B. cenocepacia clinical isolatesMIC50 / MIC90 8 / 32 μg/ml; range 0.13–32 μg/ml[3]

Literature-Reported Treatment Conditions

Method
Standardized CLSI susceptibility testing; broth microdilution for selected aerobic panels
Co-treatment
Eravacycline tested as a single agent; comparator antibiotics tested separately.
Reported limits
The concise methods refer to CLSI standards without restating incubation duration, compound vehicle or a single common tested concentration series. No conditions imported from another paper.
Methods and source locations

Compound reported in the paper: Eravacycline (TP-434); Compound label in the paper: ERV

Compound-level research findings. The tested material was not an Adooq lot; salt equivalence and lot-specific performance are not established.

sec2-1, sec2-3, sec2-4; sec3-1; Table 1 selected species rows

Growth inhibition across 445 E. coli clinical isolates: CLSI broth microdilution for aerobic organisms — Table 1, E. coli all-isolate ERV column: MIC50/90, range and n rows; sec3-1

Growth inhibition across 145 P. aeruginosa clinical isolates: Same CLSI broth microdilution panel design — Table 1, P. aeruginosa ERV column: MIC50/90, range and n rows; final paragraph sec3-1

Growth inhibition across 10 B. cenocepacia clinical isolates: Same CLSI broth microdilution panel design — Table 1, B. cenocepacia ERV column: MIC50/90, range and n rows; final paragraph sec3-1

In Vivo Studies

In an immunocompetent mouse thigh model, intravenous eravacycline at 2.5 mg/kg every 12 h produced 72-h bacterial-burden reductions of 3.32 and 4.11 log10 CFU from baseline for two MRSA isolates. Responses were smaller for the three Gram-negative isolates: 2.96, 1.81 and 1.31 log10 CFU. Efficacy therefore depended on the isolate and experimental setting. [4]

Exposure-matched eravacycline efficacy across a 72-hour mouse study

Animal study · Immunocompetent female ICR (CD-1) mice; thigh bacterial-burden time courses for two MRSA and three Enterobacteriaceae isolates. [4]

The same eravacycline regimen reduced bacterial burdens in all five isolates relative to pretreatment baseline; response varied by isolate. Effects were greater than saline controls (reported P < 0.001 for the MRSA isolates and P < 0.05 for Gram-negative isolates). Gram-negative responses were smaller and E. coli C3-14 showed little further reduction from 48 to 72 h. These are preclinical results, not human dosing recommendations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 hReduction in log10 CFU 1.79, 2.74, 3.32 log10 CFU at 24, 48, 72 h, respectively[4]
Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 hReduction in log10 CFU 1.94, 3.03, 4.11 log10 CFU at 24, 48, 72 h, respectively[4]
Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 hReduction in log10 CFU 1.61, 1.85, 2.96 log10 CFU at 24, 48, 72 h, respectively[4]
Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 hReduction in log10 CFU 0.71, 1.64, 1.81 log10 CFU at 24, 48, 72 h, respectively[4]
Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 hReduction in log10 CFU 1.14, 1.44, 1.31 log10 CFU at 24, 48, 72 h, respectively[4]

Conditions shared by the study groups

Route
Intravenous
Frequency
Every 12 h
Treatment course
72-h study; outcomes at 24, 48 and 72 h after therapy initiation.
Vehicle
Sterile 0.9% normal saline; original vial initially reconstituted with sterile water.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MRSA S. aureus 156 — eravacycline
2.5 mg/kg; paper expresses dosing solution concentration on a free-base basis.
Separate pretreatment baseline mice and time-matched saline controls; comparator-drug arms also present.1.79, 2.74, 3.32 log10 CFU reductions from baseline at 24, 48, 72 h, respectively.[4]
MRSA S. aureus 426 — eravacycline
2.5 mg/kg; paper expresses dosing solution concentration on a free-base basis.
Separate pretreatment baseline mice and time-matched saline controls; comparator-drug arms also present.1.94, 3.03, 4.11 log10 CFU reductions from baseline at 24, 48, 72 h, respectively.[4]
E. coli 373 — eravacycline
2.5 mg/kg; paper expresses dosing solution concentration on a free-base basis.
Separate pretreatment baseline mice and time-matched saline controls; comparator-drug arms also present.1.61, 1.85, 2.96 log10 CFU reductions from baseline at 24, 48, 72 h, respectively.[4]
C. freundii 26 — eravacycline
2.5 mg/kg; paper expresses dosing solution concentration on a free-base basis.
Separate pretreatment baseline mice and time-matched saline controls; comparator-drug arms also present.0.71, 1.64, 1.81 log10 CFU reductions from baseline at 24, 48, 72 h, respectively.[4]
E. coli C3-14 — eravacycline
2.5 mg/kg; paper expresses dosing solution concentration on a free-base basis.
Separate pretreatment baseline mice and time-matched saline controls; comparator-drug arms also present.1.14, 1.44, 1.31 log10 CFU reductions from baseline at 24, 48, 72 h, respectively.[4]
MRSA S. aureus 156 — eravacycline
Model: Immunocompetent female ICR (CD-1) mouse thigh infection model; MRSA S. aureus 156; eravacycline MIC 0.03 μg/ml.
Reported limits: Groups contained 3 mice (6 thighs); Gram-negative eravacycline and control experiments run in duplicate. Thighs within each mouse are paired; the independent unit used by ANOVA is not explicit. No per-arm exact uncertainty is reconstructed from bars.
MRSA S. aureus 426 — eravacycline
Model: Immunocompetent female ICR (CD-1) mouse thigh infection model; MRSA S. aureus 426; eravacycline MIC 0.25 μg/ml.
Reported limits: Groups contained 3 mice (6 thighs); Gram-negative eravacycline and control experiments run in duplicate. Thighs within each mouse are paired; the independent unit used by ANOVA is not explicit. No per-arm exact uncertainty is reconstructed from bars.
E. coli 373 — eravacycline
Model: Immunocompetent female ICR (CD-1) mouse thigh infection model; E. coli 373; eravacycline MIC 0.25 μg/ml.
Reported limits: Groups contained 3 mice (6 thighs); Gram-negative eravacycline and control experiments run in duplicate. Thighs within each mouse are paired; the independent unit used by ANOVA is not explicit. No per-arm exact uncertainty is reconstructed from bars.
C. freundii 26 — eravacycline
Model: Immunocompetent female ICR (CD-1) mouse thigh infection model; C. freundii 26; eravacycline MIC 0.125 μg/ml.
Reported limits: Groups contained 3 mice (6 thighs); Gram-negative eravacycline and control experiments run in duplicate. Thighs within each mouse are paired; the independent unit used by ANOVA is not explicit. No per-arm exact uncertainty is reconstructed from bars.
E. coli C3-14 — eravacycline
Model: Immunocompetent female ICR (CD-1) mouse thigh infection model; E. coli C3-14; eravacycline MIC 0.25 μg/ml.
Reported limits: Groups contained 3 mice (6 thighs); Gram-negative eravacycline and control experiments run in duplicate. Thighs within each mouse are paired; the independent unit used by ANOVA is not explicit. No per-arm exact uncertainty is reconstructed from bars.
Methods and source locations

Compound reported in the paper: Eravacycline; Compound label in the paper: Eravacycline, Tetraphase lot B110342

Compound-level research findings. The tested material was not an Adooq lot; salt equivalence and lot-specific performance are not established.

sec2-1/sec2-2; selected sec2-4 control/group sentences; sec2-5; sec3-2; Figures 1-5

Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 h: Thigh bacterial-burden time course; exact values from Results text — sec3-2, MRSA S. aureus 156 Results paragraph; Figure 1 and caption

Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 h: Thigh bacterial-burden time course; exact values from Results text — sec3-2, MRSA S. aureus 426 Results paragraph; Figure 2 and caption

Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 h: Thigh bacterial-burden time course; exact values from Results text — sec3-2, E. coli 373 Results paragraph; Figure 3 and caption

Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 h: Thigh bacterial-burden time course; exact values from Results text — sec3-2, C. freundii 26 Results paragraph; Figure 4 and caption

Bacterial burden reduction relative to the pretreatment baseline at 24, 48 and 72 h: Thigh bacterial-burden time course; exact values from Results text — sec3-2, E. coli C3-14 Results paragraph; Figure 5 and caption

MRSA S. aureus 156 — eravacycline · sec2-1/sec2-2; selected sec2-4 group/control sentences; sec3-2; Figure 1

MRSA S. aureus 426 — eravacycline · sec2-1/sec2-2; selected sec2-4 group/control sentences; sec3-2; Figure 2

E. coli 373 — eravacycline · sec2-1/sec2-2; selected sec2-4 group/control sentences; sec3-2; Figure 3

C. freundii 26 — eravacycline · sec2-1/sec2-2; selected sec2-4 group/control sentences; sec3-2; Figure 4

E. coli C3-14 — eravacycline · sec2-1/sec2-2; selected sec2-4 group/control sentences; sec3-2; Figure 5

Specifications

Manufacturer Adooq Bioscience
CAS Number 1207283-85-9
Formula C27H31FN4O8
Molecular Weight 558.555
Synonyms TP434
SMILES
CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Trudy H Grossman, Agata L Starosta, Corey Fyfe, et al. Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic Antimicrobial Agents and Chemotherapy (2012). PMID: 22354310 DOI: 10.1128/AAC.06187-11 Source material
  2. [2] Trudy H Grossman, Agata L Starosta, Corey Fyfe, et al. Erratum for Grossman et al., Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic Antimicrobial Agents and Chemotherapy (2015). PMID: 26276898 DOI: 10.1128/AAC.01551-15 Source material
  3. [3] J A Sutcliffe, W O'Brien, C Fyfe, et al. Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens Antimicrobial Agents and Chemotherapy (2013). PMID: 23979750 DOI: 10.1128/AAC.01288-13 Source material
  4. [4] Marguerite L Monogue, Abrar K Thabit, Yukihiro Hamada, et al. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms Antimicrobial Agents and Chemotherapy (2016). PMID: 27353265 DOI: 10.1128/AAC.00366-16 Source material

Publications

4 publications citing this product

  1. Hitender Gautam, .et al. , Indian J Med Microbiol, 2024, Mar-Apr:48:100565 PMID: 38522746
  2. Zewen Wen, .et al. , J Antibiot (Tokyo), 2022, Sep;75(9):498-508 PMID: 35896611
  3. Fan Zhang, .et al. , BMC Microbiol, 2018, 18: 211 PMID: 30545293
  4. Jin-xin Zheng, .et al. , Emerg Microbes Infect, 2018, 7: 139 PMID: 30068997

Added to your cart

View Cart Checkout
Loading...